Nivolumab,Ipilimumab,pembrolizumab,Atezolizumab
bms,merck,roche
['agent', 'rcc,(-irccs),(-srcc),(-urcc)']
disappointing results from a trial of adjuvant immunotherapy for patients with rcc who underwent nephrectomy contrast with those from a previous trial that showed benefit with another agent. #esmo22 
Medscape Oncology provides breaking medical news, references for drugs, diseases, and procedures, and free CME.